DOCSLIB.ORG

Download Clinical Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Clinical Update MONTHLY CLINICAL UPDATE KRATOM CORRELATION Q: Some of my patients have mentioned using kratom (mitragynine) to help with opioid-withdrawal relief. Should I be concerned about its potential for abuse and, if so, what adverse events have been identified? A: Although there is conflicting evidence on kratom’s abuse potential, several case reports have found a correlation between kratom use and physical dependence/addiction. Irritability, insomnia and myalgias have been observed after the discontinuation of kratom.1,2 Studies have documented nausea, tachycardia, seizures, liver toxicity and respiratory depression as side effects after use of kratom.3,4 Because of the need for more research, the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) currently discourage its use. Kratom, botanically known as Mitragyna speciosa, refers to a tropical tree found in parts of Southeast Asia belonging to the Rubiaceae family.5,6 The leaves of this tree have traditionally been used as an herbal remedy in the treatment of fatigue, cough, diarrhea, and opioid withdrawal symptoms. Kratom has conventionally been self-administered by chewing fresh leaves or adding dry, crushed leaves into herbal teas and other drinks.5,6 Due to its desirable opioid-like and psychoactive effects, its use has gained popularity in the United States. Today, it is commonly marketed as a dietary supplement in capsule or tablet form easily accessible online and in specialty stores.7 Kratom produces both analgesic and stimulant effects due to the properties of its main active alkaloids: mitragynine and 7-hydroxymitragynine (7-HMG).8 Mitragynine produces opioid-like analgesic effects by acting as a µ-opioid receptor agonist. Stimulant activity is believed to be due to inhibitory activity on serotonergic 5-HT2A receptors and activation of postsynaptic alpha-2 adrenergic receptors.9,10 Mitragynine is renally excreted after undergoing biotransformation.1,8,11 7-HMG, although a minor component, seems to demonstrate much higher levels of antinociceptive, sedative, and simulant potency.12,13 Kratom’s effects are dose-dependent in nature. Increased alertness, energy, talkativeness and social behavior along with other stimulant properties are seen at doses of 1-5 grams. Increasing doses to 5-15 grams can result in patients experiencing more opioid-like effects such as sedation, constipation, dizziness, hypotension, dry mouth and sweating. Beyond these doses, lethargy, dysphoria and euphoria are common.1,6 These effects can be seen as early as 10 minutes post-administration and usually last about 5-7 hours.14 Other common adverse effects include: anxiety, agitation, nausea, loss of appetite, tremor, insomnia, weight loss, hyperpigmentation, seizures and hallucinations.1,6 Drug-drug interactions are possible due to kratom’s potential to inhibit several major CYP450 enzymes (CYP 1A2, 3A4, and 2D6).15 Kratom is currently being researched for use in alcohol and opioid withdrawal, infection, weight loss, control of chronic or acute pain, diarrhea, and as an adjunct to diabetes therapy.16,17 Currently, both the FDA and CDC have sided against recommending its use by acknowledging a lack of substantial evidence.18 The Drug Enforcement Agency (DEA) has placed it on the “Drugs and Chemicals of Concern” list due to safety concerns with its use.19 Kratom’s lack of regulation has led to reports of poor manufacturing practices and adulteration with the addition of the more potent alkaloid, 7-HMG, in several commercial kratom products.20 Additionally, kratom may be combined with other drugs to form illicit substances; one such example is krypton, which includes O-desmethyl-tramadol. An interpretive comment alerts the provider to the possibility of krypton when tramadol is not prescribed and O-desmethyl-tramadol is detected in absence of other tramadol markers. Aegis now provides definitive testing for kratom (mitragynine) via liquid chromatography- tandem mass spectrometry (LC-MS/MS). NOVEMBER 2018 | Copyright © 2018 Aegis Sciences Corporation All Rights Reserved Please call our clinical scientists at 1-877-552-3232 if you require additional information. NOTICE: The information above is intended as a resource for health care providers. Providers should use their independent medical judgment based on the clinical needs of the patient when making determinations of who to test, what medications to test, testing frequency, and the type of testing to conduct. REFERENCES: 1. Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792-799. 2. Singh D, Muller CP, Vicknasingam BK, Mansor SM. Social Functioning of Kratom Mitragyna speciosa) Users in Malaysia. J Psychoactive Drugs. 2015; 47(9):125-131. 3. Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and Coma Following Kratom (Mitragynina speciosa Korth) Exposure. Journal of Medical Toxicology. 2010;6(4):424-426. doi:10.1007/s13181-010-0079-5. 4. Ward J, Rosenbaum C, Hernon C, Mccurdy CR, Boyer EW. Herbal Medicines for the Management of Opioid Addiction. CNS Drugs. 2011;25(12):999-1007. 5. Suwanlet S. A study of kratom eaters in Thailand. Bulletin on Narcotics. 1975;27(3):21-27. 6. Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. International Journal of Legal Medicine. 2015;130(1):127-138. 7. Kratom (Mitragyna speciosa Korth) Drug Enforcement Administration, Office of Diversion Control, Drug & Chemical Evaluation Section, Springfield, VA: US Government Printing Office (2013). http://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf. Accessed 20 April, 2018 8. Hassan Z, Muzaimi M, Navaratnam V, et al. From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience & Biobehavioral Reviews. 2013;37(2):138-151. 9. Babu KM, Mccurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorumand Kratom. Clinical Toxicology. 2008;46(2):146-152. 10. Matsumoto K, Horie S, Ishikawa H, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sciences. 2004;74(17):2143-2155. 11. Kratom (Mitragyna speciosa) drug profile. European Monitoring Centre for Drugs and Drug Addiscitoin, January, 2015. http://www.emcdda. europa.eu/publications/drug-profiles/kratom. Accessed 20 April 2018 12. Takayama H. Chemistry and Pharmacology of Analgesic Indole Alkaloids from the Rubiaceous Plant, Mitragyna speciosa. ChemInform. 2004;35(52). doi:10.1002/chin.200452220. 13. Thongpradichote S, Matsumoto K, Tohda M, et al. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally- admintstered mitragynine in mice. Life Sciences. 1998;62(16):1371-1378. 14. Wananukul W, Trakulsrichai S, Sathirakul K, et al. Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy. 2015:2421. 15. Takayama H, Ishikawa H, Kurihara M, et al. Studies on the Synthesis and Opioid Agonistic Activities of Mitragynine-Related Indole Alkaloids: Discovery of Opioid Agonists Structurally Different from Other Opioid Ligands. Journal of Medicinal Chemistry. 2002;45(9):1949-1956. 16. Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. International Journal of Drug Policy. 2010;21(4):283-288. 17. Akinsinde KA, Olukoya DK. Vibriocidal activities of some local herbs. J Diarrhoeal Dis Res. 1995;13(2):127-129. 18. Office of the Commissioner. Public Health Focus - FDA and Kratom. U S Food and Drug Administration Home Page. https://www.fda.gov/ newsevents/publichealthfocus/ucm584952.htm. Accessed April 20, 2018. 19. Drugs of Concern. In: Drugs of Abuse: a DEA Resource Guide. 2017th ed. Washington, DC; U.S. Department of Justice, Drug Enforcement Administration. 2017:82-85. 20. Lydecker AG, Sharma A, Mccurdy CR, Avery BA, Babu KM, Boyer EW. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. Journal of Medical Toxicology. 2016;12(4):341-349. NOVEMBER 2018 | Copyright © 2018 Aegis Sciences Corporation All Rights Reserved.
Load more

Recommended publications
  • 1 Title Page Pharmacological Comparison of Mitragynine and 7
    JPET Fast Forward. Published on December 31, 2020 as DOI: 10.1124/jpet.120.000189 This article has not been copyedited and formatted. The final version may differ from this version. JPET-AR-2020-000189R1: Obeng et al. Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Morphine-Like Discriminative-Stimulus Effects in Rats. Title Page Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for Mu-Opioid Receptor and Opioid-Like Behavioral Effects in Rats Samuel Obeng1,2,#, Jenny L. Wilkerson1,#, Francisco León2, Morgan E. Reeves1, Luis F. Restrepo1, Lea R. Gamez-Jimenez1, Avi Patel1, Anna E. Pennington1, Victoria A. Taylor1, Nicholas P. Ho1, Tobias Braun1, John D. Fortner2, Morgan L. Crowley2, Morgan R. Williamson1, Victoria L.C. Pallares1, Marco Mottinelli2, Carolina Lopera-Londoño2, Christopher R. McCurdy2, Lance R. McMahon1, and Takato Hiranita1* Downloaded from Departments of Pharmacodynamics1 and Medicinal Chemistry2, College of Pharmacy, University of Florida jpet.aspetjournals.org #These authors contributed equally Recommended section: Behavioral Pharmacology at ASPET Journals on September 29, 2021 Correspondence: *Takato Hiranita, Ph.D. Department of Pharmacodynamics, College of Pharmacy, University of Florida 1345 Center Drive, Gainesville, FL 32610 Email: [email protected] Phone: +1.352.294.5411 Fax: +1.352.273.7705 Keywords: kratom, mitragynine, 7-hydroxymitragynine, morphine, opioid, discriminative stimulus Conflicts of Interests or Disclaimers: None Manuscript statistics: Number of text pages: 56 Number of tables: 7 Number of figures: 10 Number of supplementary Tables: 4 Number of supplementary figures: 7 1 JPET Fast Forward. Published on December 31, 2020 as DOI: 10.1124/jpet.120.000189 This article has not been copyedited and formatted.
    [Show full text]
  • ANSM Annual Report 2019 2
    1 EDITORIAL ........................................................................................................................................................ 3 HIGHLIGHTS IN 2019......................................................................................................................................... 5 KEY FIGURES IN 2019 ........................................................................................................................................ 5 OUR ESTABLISHMENT ...................................................................................................................................... 7 OUR INTERACTIONS WITH OUR ENVIRONMENT............................................................................................. 14 OUR ACTIVITY ................................................................................................................................................ 48 ENSURING THE SAFETY OF HEALTH PRODUCTS .............................................................................................................. 49 FACILITATING ACCESS TO INNOVATION AND DEVELOPMENT .......................................................................................... 141 OUR RESOURCES .......................................................................................................................................... 174 GLOSSARY .................................................................................................................................................... 196 APPENDICES
    [Show full text]
  • Site Selective C–H Functionalization of Mitragyna Alkaloids Reveals A
    ARTICLE https://doi.org/10.1038/s41467-021-23736-2 OPEN Site selective C–H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy Srijita Bhowmik 1,12, Juraj Galeta 1,2,12, Václav Havel 1, Melissa Nelson 3,4, Abdelfattah Faouzi 5,6, Benjamin Bechand1, Mike Ansonoff 7, Tomas Fiala 1,8, Amanda Hunkele5,9, Andrew C. Kruegel1, ✉ John. E. Pintar 7, Susruta Majumdar 5, Jonathan A. Javitch 3,4 & Dalibor Sames 1,10,11 1234567890():,; Mitragynine (MG) is the most abundant alkaloid component of the psychoactive plant material “kratom”, which according to numerous anecdotal reports shows efficacy in self-medication for pain syndromes, depression, anxiety, and substance use disorders. We have developed a synthetic method for selective functionalization of the unexplored C11 position of the MG scaffold (C6 position in indole numbering) via the use of an indole-ethylene glycol adduct and subsequent iridium-catalyzed borylation. Through this work we discover that C11 represents a key locant for fine-tuning opioid receptor signaling efficacy. 7-Hydroxymitragynine (7OH), the parent compound with low efficacy on par with buprenorphine, is transformed to an even lower efficacy agonist by introducing a fluorine substituent in this position (11-F-7OH), as demonstrated in vitro at both mouse and human mu opioid receptors (mMOR/hMOR) and in vivo in mouse analgesia tests. Low efficacy opioid agonists are of high interest as candidates for generating safer opioid medications with mitigated adverse effects. 1 Department of Chemistry, Columbia University, New York, NY, USA. 2 Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague), 160 00 Prague 6, Czech Republic.
    [Show full text]
  • Understanding the Physicochemical Properties of Mitragynine, a Principal Alkaloid of Mitragyna Speciosa, for Preclinical Evaluation
    Molecules 2015, 20, 4915-4927; doi:10.3390/molecules20034915 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Article Understanding the Physicochemical Properties of Mitragynine, a Principal Alkaloid of Mitragyna speciosa, for Preclinical Evaluation Surash Ramanathan 1, Suhanya Parthasarathy 1,*, Vikneswaran Murugaiyah 2, Enrico Magosso 3, Soo Choon Tan 4 and Sharif Mahsufi Mansor 1 1 Centre for Drug Research, Universiti Sains Malaysia, Penang 11800, Malaysia 2 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia 3 Advanced Medical & Dental Institute, Universiti Sains Malaysia, Bertam, Kepala Batas, Penang 13200, Malaysia 4 Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, Malaysia * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +604-653-2173; Fax: +604-656-8669. Academic Editor: Patricia Valentao Received: 12 January 2015 / Accepted: 27 February 2015 / Published: 18 March 2015 Abstract: Varied pharmacological responses have been reported for mitragynine in the literature, but no supportive scientific explanations have been given for this. These studies have been undertaken without a sufficient understanding of the physicochemical properties of mitragynine. In this work a UV spectrophotometer approach and HPLC-UV method were employed to ascertain the physicochemical properties of mitragynine. The pKa of mitragynine measured by conventional UV (8.11 ± 0.11) was in agreement with the microplate reader determination (8.08 ± 0.04). Mitragynine is a lipophilic alkaloid, as indicated by a logP value of 1.73. Mitragynine had poor solubility in water and basic media, and conversely in acidic environments, but it is acid labile. In an in vitro dissolution the total drug release was higher for the simulated gastric fluid but was prolonged and incomplete for the simulated intestinal fluid.
    [Show full text]
  • Poison Act 1952
    LAWS OF MALAYSIA _____________ ONLINE VERSION OF UPDATED TEXT OF REPRINT _____________ Act 366 POISONS ACT 1952 As at 1 February 2019 2 POISONS ACT 1952 First enacted … … … … 1952 (Ord. No. 29 of 1952) Revised … … … … 1989 (Act 366 w.e.f. 13 April 1989) Latest amendment made by P.U. (A) 8/2019 which came into operation on … … 10 January 2019 PREVIOUS REPRINTS First Reprint ... ... ... ... ... 2001 Second Reprint ... ... ... ... ... 2006 3 LAWS OF MALAYSIA Act 366 POISONS ACT 1952 ARRANGEMENT OF SECTIONS Section 1. Short title and application 2. Interpretation 3. Establishment of Poisons Board 4. Proceedings of Board 5. Powers of Board to regulate proceedings 6. Power of Minister to amend Poisons List 7. Application of the Act 8. Control of imports of poisons 9. Packaging, labelling and storing of poisons 10. Transport of poisons 11. Control of manufacture of preparations containing poison 12. Control of compounding of poisons for use in medical treatment 13. Possession for sale of poison and sale of poison in contravention of this Act an offence 14. Control of acetylating substances 15. Sale of poisons by wholesale 16. Sale of poisons by retail 17. Prohibition of sale to persons under 18 18. Restriction on the sale of Part I poisons generally 19. Supply of poisons for the purpose of treatment by professional men 20. Group A Poisons 21. Group B Poisons 4 Laws of Malaysia ACT 366 Section 22. Group C Poisons 23. Group D Poisons 24. Prescription book 25. Sale of Part II Poisons 26. Licences 27. Register of licences 28. Annual list to be published 29.
    [Show full text]
  • Mitragynine Attenuates Morphine Withdrawal Effects in Rats—A Comparison with Methadone and Buprenorphine
    ORIGINAL RESEARCH published: 07 May 2020 doi: 10.3389/fpsyt.2020.00411 Mitragynine Attenuates Morphine Withdrawal Effects in Rats—A Comparison With Methadone and Buprenorphine Rahimah Hassan 1, Cheah Pike See 2, Sasidharan Sreenivasan 3, Sharif M. Mansor 1, Christian P. Müller 4* and Zurina Hassan 1,5* 1 Centre for Drug Research, Universiti Sains Malaysia, Minden, Malaysia, 2 Department of Human Anatomy, Faculty of Medicine and Health Sciences, University Putra Malaysia, Serdang, Malaysia, 3 Institute for Research in Molecular Medicine, Universiti Sains Malaysia, Minden, Malaysia, 4 Section of Addiction Medicine, Department of Psychiatry and Psychotherapy, University Clinic, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany, 5 Addiction Behaviour and Neuroplasticity Laboratory, National Neuroscience Institute, Singapore, Singapore Edited by: Simona Zaami, Background: Opiate addiction is a major health problem in many countries. A crucial Sapienza University of Rome, component of the medical treatment is the management of highly aversive opiate Italy Reviewed by: withdrawal signs, which may otherwise lead to resumption of drug taking. In a Fabrizio Schifano, medication-assisted treatment (MAT), methadone and buprenorphine have been University of Hertfordshire, implemented as substitution drugs. Despite MAT effectiveness, there are still limitations United Kingdom Ornella Corazza, and side effects of using methadone and buprenorphine. Thus, other alternative therapies University of Hertfordshire, with less side effects, overdosing, and co-morbidities are desired. One of the potential United Kingdom pharmacotherapies may involve kratom's major indole alkaloid, mitragynine, since kratom *Correspondence: (Mitragyna speciosa Korth.) preparations have been reported to alleviate opiate Christian P. Müller [email protected] withdrawal signs in self-treatment in Malaysian opiate addicts.
    [Show full text]
  • A Simple and Cost Effective Isolation and Purification Protocol of Mitragynine from Mitragyna Speciosa Korth (Ketum) Leaves
    The Malaysian Journal of Analytical Sciences, Vol 15 No 1 (2011): 54 - 60 A SIMPLE AND COST EFFECTIVE ISOLATION AND PURIFICATION PROTOCOL OF MITRAGYNINE FROM MITRAGYNA SPECIOSA KORTH (KETUM) LEAVES (Satu Protokol Pengasingan Mitragina daripada Daun Mitragyna speciosa Korth (Ketum) yang Mudah dan Kos Efektif) Goh Teik Beng1* , Mohamad Razak Hamdan1, Mohammad Jamshed Siddiqui2, Mohd Nizam Mordi1 and Sharif Mahsufi Mansor1 1Centre of Drug Research, 2 School of Pharmaceutical Science, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia. *Corresponding author: [email protected] Abstract The objective of the present study was to develop a simple and cost effective method for the isolation of mitragynine from Mitragyna speciosa Korth leaves. The results of our study showed that around 0.088 % (w/w) pure mitragynine was obtained by this newly developed method with a purity of 99.0 % (w/w) based on GC-MS analysis. Moreover, the recovery of the pure mitragynine from the chloroform extract was also more than 95.0 %. Advantages of this new method were simpler, faster and more economical. In conclusion this simple and cost effective method helps to isolate mitragynine with higher purity in comparison with the published methods. Keywords: Mitragynine speciosa Korth, mitragynine, mitragynine extraction Abstrak Objektif kajian ini adalah untuk membangunkan satu kaedah yang mudah dan kos efektif untuk pengasingan mitraginina daripada daun Mitragyna speciosa Korth. Keputusan kajian menunjukkan bahawa lebih kurang 0.088 % (w/w) mitraginina tulen telah diperolehi dengan menggunakan kaedah baru yang dibangunkan ini dengan ketulenan 99.0 % (w/w) berdasarkan analysis GC-MS. Malahan, hasil pemerolehan semula mitraginina tulen daripada ekstrak kloroform juga melebihi 95.0 %.
    [Show full text]
  • Emerging Drugs of Abuse
    Emerging Drugs of Abuse Julie Kmiec, DO and Bill Morrone, DO, MS Disclosures • Julie Kmiec, DO • I have no financial conflicts of interest • William Morrone, DO • I have no financial conflicts of interest 2 Objectives • At the end of the lecture, participants should be able to • Name substances which have been increasing in use over the past several years • Discuss the mechanism of action of these substances • Discuss the intoxication and withdrawal syndromes of these substances • Describe how to treat intoxication or withdrawal from these substances Background • Mitragyna speciosa, from coffee plant family • Psychoactive herb from Southeast Asia with opioid and/or stimulant activity, depending on amount used • Raw plant contains higher concentrations of mitragynine than 7- hydroxymitragynine (7-HMG) • Traditionally used to • Boost energy • Reduce cough • Reduce depression • Alleviate pain • Also used as a substitute for opium Kratom Background • In the US, kratom is • Unregulated herbal remedy • In 2016, DEA announced plan to move to Schedule 1, huge outcry and DEA withdrew notice of intent • Several stories of how it was a harmless, good alternative for some as opioid substitute • DEA put it on "Drugs and Chemicals of Concern” list Background: Kratom • Sold as dietary supplement • Sold in smoke shops, online • Available in capsules, whole leaves, liquid, powder • Can be consumed as a tea • Not detectable by standard urine drug testing Psychopharmacology • Partial agonists for the mu-opiate receptor (and possibly kappa receptors) • Bind
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 30 March 2021 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that appeared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Coun- cil, hereby makes the following regulations. Contents Page 1 Title and commencement 5 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 9 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 30 March 2021 Part 2 Standards 4 Standards for medicines, related products, medical devices, 10 cosmetics, and surgical dressings 4A Standard for CBD products 10 5 Pharmacist may dilute medicine in particular case 11 6 Colouring substances [Revoked] 11 Part 3 Advertisements 7 Advertisements not to claim official approval 11 8 Advertisements for medicines 11 9 Advertisements for related products 13 10 Advertisements
    [Show full text]
  • Director's Report to the National Advisory Council on Drug Abuse;
    TABLE OF CONTENTS RESEARCH HIGHLIGHTS…………….………………………………………………………. 1 GRANTEE HONORS AND AWARDS…………………………………………………………. 18 STAFF HONORS AND AWARDS…………………………………………………………….... 20 STAFF CHANGES…………………………………………………………………………….…. 22 IN MEMORIAM.……………………………………………………………………………….… 23 RESEARCH HIGHLIGHTS BASIC AND BEHAVIORAL RESEARCH A Paranigral VTA Nociceptin Circuit That Constrains Motivation For Reward Parker KE, Pedersen CE, Gomez AM, Spangler SM, Walicki MC, Feng SY, Stewart SL, Otis JM, Al-Hasani R, McCall JG, Sakers K, Bhatti DL, Copits BA, Gereau RW, Jhou T, Kash TJ, Dougherty JD, Stuber GD, Bruchas JR. Cell 2019 Jul 25; 178(3): 653-671. Nociceptin and its receptor are widely distributed throughout the brain in regions associated with reward behavior, yet how and when they act is unknown. Here, we dissected the role of a nociceptin peptide circuit in reward seeking. We generated a prepronociceptin (Pnoc)-Cre mouse line that revealed a unique subpopulation of paranigral ventral tegmental area (pnVTA) neurons enriched in prepronociceptin. Fiber photometry recordings during progressive ratio operant behavior revealed pnVTAPnoc neurons become most active when mice stop seeking natural rewards. Selective pnVTAPnoc neuron ablation, inhibition, and conditional VTA nociceptin receptor (NOPR) deletion increased operant responding, revealing that the pnVTAPnoc nucleus and VTA NOPR signaling are necessary for regulating reward motivation. Additionally, optogenetic and chemogenetic activation of this pnVTAPnoc nucleus caused avoidance and decreased motivation
    [Show full text]
  • Kratom (Mitragyna Speciosa Korth) for a New Medicinal: a Review of Pharmacological and Compound Analysis
    Review Volume 11, Issue 2, 2021, 9704 - 9718 https://doi.org/10.33263/BRIAC112.97049718 Kratom (Mitragyna speciosa Korth) for a New Medicinal: a Review of Pharmacological and Compound Analysis Adang Firmansyah 1* , Melvia Sundalian 1 , Muhammad Taufiq 1* 1 Sekolah Tinggi Farmasi Indonesia, Bandung, Indonesia * Correspondence: [email protected] (A.F.); [email protected] (M.T.); Scopus Author ID 57216094882 Received: 25.08.2020; Revised: 12.09.2020; Accepted: 14.09.2020; Published: 16.09.2020 Abstract: Mitragyna speciosa Korth. (Rubiaceae) a tree found in Southeast Asia (Thailand, Indonesia, Malaysia, Myanmar, Philippines, and Papua New Guinea. Traditionally, the Mitragyna speciosa was used to alleviate pain, hypertension, cough, diarrhea, and as a substitute for morphine in treating addicts. Association of Southeast Asian Nations refers to kratom as a drug. Kratom contains more than 40 types of alkaloids, including Mitragynine speciosa, as many as (66.2%) and their derivatives, speciogynine (6.6%), speciociliatine (0.8%), paynantheine (8.6%), 7-hydroxymitragynine (2%). The article was created to provide information related to the pharmacological effects of kratom, kratom compound analysis, and the potential of compounds from kratom to become new drugs. The method used in this research is to review and analyze kratom articles from research papers, bibliographic reviews, and case reports included, research conducted in Indonesia and in English. The main purpose of this review is not only to understand the chemical content, benefits of kratom, and analytical methodologies for analysis, but also the use of kratom secondary metabolites as therapeutic drugs and the side effects caused by kratom, to help health professionals assess the content of compounds from kratom worthy of being new drugs.
    [Show full text]
  • CEDIATM Mitragynine (Kratom) Assay
    CEDIATM Mitragynine (Kratom) Assay For Criminal Justice and Forensic Use Only 10026604 (3 x 17 mL Kit) 10026612 (65 mL Kit) Intended Use Warnings and Precautions The CEDIATM Mitragynine Assay is a homogenous enzyme immunoassay for the qualitative The reagents are harmful if swallowed. and/or semi-quantitative estimation of mitragynine in human urine at a cutoff concentration Danger: of 50 ng/mL. The assay provides a simple and rapid analytical screening procedure to detect Powder reagents contain ≤ 53% w/w Bovine Serum Albumin (BSA) fragments and ≤ 2% w/w mitragynine in human urine. This product is intended to be used by trained professionals Sodium Azide. only. The assay provides only a preliminary analytical test result. A more specific Liquid reagents contain ≤ 0.03% Bovine Serum, ≤ 0.09% Sodium Azide, and ≤ 0.09% alternative chemical method must be used to obtain a confirmed analytical result. Gas Drug-Specific Antibody (Mouse). chromatography/ mass spectrometry (GC/MS) or Liquid chromatography/ tandem mass spectrometry (LC-MS/MS) is the preferred confirmatory method. H317 - May cause allergic skin reaction. H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled. Clinical and professional judgment should be applied to any drugs of abuse test result, H412 - Harmful to aquatic life with long-lasting effect particularly when preliminary results are used. For Criminal Justice and Forensic Use Only. EUH032 - Contact with acids liberates very toxic gas. Summary and Explanation of the Test Avoid breathing dust/mist/vapors/spray. Contaminated work clothing should not be allowed Kratom, the common name for the plant Mitragyna speciosa, is commonly used in Southeast out of the workplace.
    [Show full text]